2 Information about pembrolizumab combination

2 Information about pembrolizumab combination

Market authorisation indication

Pembrolizumab (Keytruda, Merck, Sharp & Dohme), plus pemetrexed and carboplatin or cisplatin has a marketing authorisation for 'the first-line treatment of metastatic non-squamous non-small-cell lung carcinoma (NSCLC) in adults whose tumours have no epidermal growth factor receptor or anaplastic lymphoma kinase-positive tumour mutations'.

Dosage in the marketing authorisation

200 mg every 3 weeks by intravenous infusion. The summary of product characteristics recommends treatment with pembrolizumab until disease progression or unacceptable toxicity.


£1,315.00 per 50 mg vial (excluding VAT; British national formulary online, accessed October 2018).

The company has a commercial arrangement. This makes pembrolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)